Immal Pharmeceuticals Inc Brooklyn, NY - 11230

Immal Pharmeceuticals Inc is categorized under Wholesale Pharmaceutical Products in Brooklyn, NY and active since 1997.

Immal Pharmeceuticals Inc was established in 1997, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Wholesale Pharmaceutical Products business, which does work in the B2B market, and is classified as a Wholesale Pharmaceutical Products, under code number 424210 by the NAICS.

If you are seeking more information, feel free to contact Leo Ehrlich at the company’s single location by writing to 1382 East 18th St, Brooklyn, New York NY 11230 or by phoning (505) 315-6495. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Immal Pharmeceuticals Inc
Contact Person: Leo Ehrlich
Address: 1382 East 18th St, Brooklyn, New York 11230
Phone Number: (505) 315-6495
Annual Revenue (USD): $100.000 to $499.999
Founded: 1997
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Wholesale Pharmaceutical Products
SIC Code: 5122
NAICS Code: 424210
Share This Business:

Immal Pharmeceuticals Inc was started in 1997 to provide professional Wholesale Pharmaceutical Products under the SIC code 5122 and NAICS code 424210. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.

Feel free to contact Leo Ehrlich for inquiries that concern Immal Pharmeceuticals Inc by calling the company number (505) 315-6495, as your correspondence is most welcome. Additionally, the physical location of the single location of Immal Pharmeceuticals Inc can be found at the coordinates 40.616787,-73.957063 as well as the street address 1382 East 18th St in Brooklyn, New York 11230.

For its online presence, you may visit Immal Pharmeceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.